A groundbreaking study revealed that Novo Nordisk’s diabetes pill, Rybelsus, reduces the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo. This significant finding emerged from a late-stage trial involving over 9,600 patients aged 50 and older, who were monitored for an average of nearly four years. The trial included patients with diabetes and established heart disease, with or without chronic kidney disease. By the end of the study, 12% of Rybelsus users and 13.8% of placebo users experienced the aforementioned cardiovascular events. Rybelsus specifically lowered the risk of non-fatal heart attacks by 26%, non-fatal strokes by 12%, and cardiovascular-related death by 7%. The results were consistent across various patient subgroups. While gastrointestinal side effects were common, they rarely led to discontinuation of the medication. This data supports Rybelsus as a promising new treatment option for managing both diabetes and cardiovascular health.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
